Sequence information
Variant position: 299 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 721 The length of the canonical sequence.
Location on the sequence:
NEEILGNQIHMHVTAKEYGA
R VSNLHMYSAVCADVIRRWVY
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human NEEILGNQIHMHVTAKEYGAR VSNLHMYSAVCADVIRRWVY
Mouse NEEVLGNQIHLHVTTREYGAR VSNLHMYSAVCADVIRRWVY
Rat NEEILGNQIHLHVTSREYGAR VSNLHMYSAVCADVIRRWVY
Rabbit NEEILGNQIHMHVTTREYGAR VSNLHMYSAVCADVIRRWVY
Slime mold TSDLLDYKLSAYVLQGEYAAR VKDLRTYHSVSKDIIHRWTF
Baker's yeast SSDILGKHIYAYLT-DEYAVR VESWQTYDTISQDFLGRWCY
Fission yeast TSDLLGKKIHCHVAKENYAAR VRSLQTYDAISKDVLSRWVY
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
2 – 721
Translation initiation factor eIF-2B subunit epsilon
Beta strand
297 – 299
Literature citations
Subunits of the translation initiation factor eIF2B are mutant in leukoencephalopathy with vanishing white matter.
Leegwater P.A.J.; Vermeulen G.; Koenst A.A.M.; Naidu S.; Mulders J.; Visser A.; Kersbergen P.; Mobach D.; Fonds D.; van Berkel C.G.M.; Lemmers R.J.L.F.; Frants R.R.; Oudejans C.B.M.; Schutgens R.B.H.; Pronk J.C.; van der Knaap M.S.;
Nat. Genet. 29:383-388(2001)
Cited for: VARIANTS VWM GLY-73; ALA-91; PHE-106; HIS-113; HIS-299; GLY-315; HIS-315; PRO-339; GLN-339; TRP-339; VAL-386; ALA-430; ARG-628 AND LYS-650; VARIANT VAL-587;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.